Ausgabe Sonderheft 3/2004
Inhalt (20 Artikel)
Current limitations of radiofrequency ablation in renal cell carcinoma
Michael A. S. Jewett
Prediction of site-specific metastases in surgically treated nonmetastatic renal cell cancer
I. Frank, H. Zincke
Human renal cell carcinoma inhibits dendritic cell maturation and functions
E. Y. Song, M. R. Shurin, I. L. Tourkova, G. Chatta, G. V. Shurin
Tumor-induced dysfunction in T lymphocytes: increased sensitivity to apoptosis
J. H. Finke, C. Tannenbaum, W. Storkus, P. Rayman, T. Das, K. Biswas, A. Richmond, C. Moon, M. Thornton, I. Gill, A. Novick, R. Bukowski
The cellular and molecular basis of natural antitumor immunity in renal cell carcinoma patients
Dolores J. Schendel, C. S. Falk, B. Frankenberger, E. Noessner, J. Schleypen, H. Pohla
Predicting survival of patients with metastatic renal cell carcinoma
R. J. Motzer, M. Mazumdar
HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC
J. A. Ellerhorst, W. H. Hildebrand, J. W. Cavett, M. A. Fernandez-Vina, S. Hodges, N. Poindexter, H. Fischer, E. A. Grimm
Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy
Edith Huland, H. Heinzer, R. A. Jörres, D. Loppow, H. Huland
Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma
Robert A. Figlin, H. Alvin, C. L. Meinhardt
Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IXG250/MN
Peter Mulders, I. Bleumer, F. Debruyne, E. Oosterwijk
Genetic pathways and new progression markers for prostate cancer defined by microsatellite allelotyping
Rolf von Knobloch, Lutz Konrad, Peter J. Barth, Heidrun Brandt, Sebastian Wille, Axel Heidenreich, Roland Moll, Rainer Hofmann